|
|
Blood, 1 November 2004, Vol. 104, No. 9, pp. 2655-2660.
Prepublished online as a Blood First Edition Paper on July 1, 2004; DOI 10.1182/blood-2003-09-3032.
 Previous Article | Table of Contents | Next Article 
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study
Martin A. Champagne,
Renaud Capdeville,
Mark Krailo,
Wenchun Qu,
Bin Peng,
Marianne Rosamilia,
Martine Therrien,
Ulrike Zoellner,
Susan M. Blaney, and
Mark Bernstein
From the Hôpital Ste-Justine, Montréal, QC, Canada; the Children's Oncology Group, Arcadia, AB, Canada; Baylor College of Medicine, Houston, TX; and Novartis Pharma AG, Basel, Switzerland.
The purpose of this study was to determine dose-limiting toxicities and pharmacokinetics of imatinib in children with refractory or recurrent Philadelphia chromosome-positive (Ph+) leukemias. Oral imatinib was administered daily at dose levels ranging from 260 to 570 mg/m2. Plasma pharmacokinetic studies were performed on days 1 and 8 of course 1. There were 31 children who received 479 courses of imatinib. The most common toxicities encountered, which occurred in less than 5% of courses, were grade 1 or 2 nausea, vomiting, fatigue, diarrhea, and reversible increases in serum transaminases. One patient at the 440-mg/m2 dose level had dose-limiting weight gain. There were no other first-course dose-limiting toxicities. A maximum tolerated dosage was not defined. Among 12 chronic myeloid leukemia (CML) patients evaluable for cytogenetic response, 10 had a complete response and 1 had a partial response. Among 10 acute lymphoblastic leukemia (ALL) patients evaluable for morphologic response, 7 achieved an M1 and 1 achieved an M2 bone marrow. We observed marked interpatient variability in the pharmacokinetic parameters. In conclusion, we found that daily oral imatinib is well tolerated in children at doses ranging from 260 to 570 mg/m2. Doses of 260 and 340 mg/m2 provide systemic exposures similar to those of adults who are treated with daily doses of 400 and 600 mg, respectively. (Blood. 2004;104:2655-2660)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
N. P. Agaram, M. P. Laquaglia, B. Ustun, T. Guo, G. C. Wong, N. D. Socci, R. G. Maki, R. P. DeMatteo, P. Besmer, and C. R. Antonescu
Molecular Characterization of Pediatric Gastrointestinal Stromal Tumors
Clin. Cancer Res.,
May 15, 2008;
14(10):
3204 - 3215.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Oudot, M.-F. Auclerc, V. Levy, R. Porcher, C. Piguet, Y. Perel, V. Gandemer, M. Debre, C. Vermylen, B. Pautard, et al.
Prognostic Factors for Leukemic Induction Failure in Children With Acute Lymphoblastic Leukemia and Outcome After Salvage Therapy: The FRALLE 93 Study
J. Clin. Oncol.,
March 20, 2008;
26(9):
1496 - 1503.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Fuster, M. Bermudez, A. Galera, M. E. Llinares, D. Calle, and F. J. Ortuno
Imatinib mesylate in combination with chemotherapy in four children with de novo and advanced stage Philadelphia chromosome-positive acute lymphoblastic leukemia
Haematologica,
December 1, 2007;
92(12):
1723 - 1724.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. F. Pollack, R. I. Jakacki, S. M. Blaney, M. L. Hancock, M. W. Kieran, P. Phillips, L. E. Kun, H. Friedman, R. Packer, A. Banerjee, et al.
Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: A Pediatric Brain Tumor Consortium report
Neuro-oncol,
April 1, 2007;
9(2):
145 - 160.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
